A pauci-symptomatic case of documented Hantavirus (Puumala) infection in a patient under anti-TNF treatment

Journal of Clinical Virology

Volumn 50, Issue 3, 2011, Pages 247-248

  Moutschen, P ^a   Bourhaba, M ^a   Frippiat, F ^a   Giot, J B ^a   Meuris, C ^a   Leonard P ^a   Moutschen, M ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Anti TNF therapy; Hantavirus infection; Immunosuppression

Indexed keywords

ADALIMUMAB; IMMUNOGLOBULIN G; INFLIXIMAB; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; ARTICLE; CASE REPORT; CROHN DISEASE; DISEASE ASSOCIATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEVER; HANTAVIRUS INFECTION; HUMAN; IMMUNOCOMPROMISED PATIENT; MALE; PRIORITY JOURNAL; SKIN TOXICITY; TREATMENT DURATION;

ADOLESCENT; ANTIBODIES, VIRAL; CROHN DISEASE; HANTAVIRUS; HANTAVIRUS INFECTIONS; HUMANS; IMMUNOLOGIC FACTORS; MALE; SEROLOGIC TESTS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79851513485     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2010.11.016     Document Type: Article

References (18)

1. Heyman P., Vaheri A., Lundkvist A., Avsic-Zupanc T. Hantavirus infections in Europe: from virus carriers to a major public-health problem. Expert Rev Anti Infect Ther 2009, 7:205-217.
2. Makela S., Kokkonen L., Ala-Houhala I., Groundstroem K., Harmoinen A., Huhtala H., et al. More than half of the patients with acute Puumala hantavirus infection have abnormal cardiac findings. Scand J Infect Dis 2009, 41:57-62.
3. Hautala N., Kauma H., Vapalahti O., Mahonen S.M., Vainio O., Vaheri A., et al. Prospective study on ocular findings in acute Puumala hantavirus infection in hospitalised patients. Br J Ophthalmol 2010, 10.1136/bjo.2010.185413.
4. Mustonen J., Partanen J., Kanerva M., Pietilä K., Vapalahti O., Pasternack A., Vaheri A. Association of HLA B27 with benign clinical course of nephropathia epidemica caused by Puumala hantavirus. Scand J Immunol 1998, 47:277-279.
5. Mustonen J., Partanen J., Kanerva M., Pietilä K., Vapalahti O., Pasternack A., Vaheri A. Genetic susceptibility to severe course of nephropathia epidemica caused by Puumala hantavirus. Kidney Int 1996, 49:217-221.
6. Mustonen J., Huttunen N.P., Partanen J., Baer M., Paakkala A., Vapalahti O., Uhari M. Human leukocyte antigens B8-DRB1*03 in pediatric patients with nephropathia epidemica caused by Puumala hantavirus. Pediatr Infect Dis J 2004, 23:959-961.
7. Kanerva M., Vaheri A., Mustonen J., Partanen J. High-producer allele of tumour necrosis factor-alpha is part of the susceptibility MHC haplotype in severe puumala virus-induced nephropathia epidemica. Scand J Infect Dis 1998, 30:532-534.
8. Makela S., Hurme M., Ala-Houhala I., Mustonen J., Koivisto A.M., Partanen J., et al. Polymorphism of the cytokine genes in hospitalized patients with Puumala hantavirus infection. Nephrol Dial Transplant 2001, 16:1368-1373.
9. Makela S., Mustonen J., Ala-Houhala I., Hurme M., Partanen J., Vapalahti O., et al. Human leukocyte antigen-B8-DR3 is a more important risk factor for severe Puumala hantavirus infection than the tumor necrosis factor-alpha(-308) G/A polymorphism. J Infect Dis 2002, 186:843-846.
10. Maes P., Clement J., Groeneveld P.H., Colson P., Huizinga T.W., Van Ranst M. Tumor necrosis factor-alpha genetic predisposing factors can influence clinical severity in nephropathia epidemica. Viral Immunol 2006, 19:558-564.
11. Linderholm M., Ahlm C., Settergren B., Waage A., Tarnvik A. Elevated plasma levels of tumor necrosis factor (TNF)-alpha, soluble TNF receptors, interleukin (IL)-6, and IL-10 in patients with hemorrhagic fever with renal syndrome. J Infect Dis 1996, 173:38-43.
12. Kanerva M., Mustonen J., Vaheri A. Pathogenesis of puumala and other hantavirus infections. Rev Med Virol 1998, 8:67-86.
13. Makela S., Mustonen J., Ala-Houhala I., Hurme M., Koivisto A.M., Vaheri A., et al. Urinary excretion of interleukin-6 correlates with proteinuria in acute Puumala hantavirus-induced nephritis. Am J Kidney Dis 2004, 43:809-816.
14. Outinen T.K., Makela S.M., Ala-Houhala I.O., Huhtala H.S., Hurme M., Paakkala A.S., et al. The severity of Puumala hantavirus induced nephropathia epidemica can be better evaluated using plasma interleukin-6 than C-reactive protein determinations. BMC Infect Dis 2010, 10:132.
15. Khaiboullina S.F., Netski D.M., Krumpe P., St Jeor S.C. Effects of tumor necrosis factor alpha on sin nombre virus infection in vitro. J Virol 2000, 74:11966-11971.
16. Taylor S.L., Frias-Staheli N., Garcia-Sastre A., Schmaljohn C.S. Hantaan virus nucleocapsid protein binds to importin alpha proteins and inhibits tumor necrosis factor alpha-induced activation of nuclear factor kappa B. J Virol 2009, 83:1271-1279.
17. Seitsonen E., Hynninen M., Kolho E., Kallio-Kokko H., Pettila V. Corticosteroids combined with continuous veno-venous hemodiafiltration for treatment of hantavirus pulmonary syndrome caused by Puumala virus infection. Eur J Clin Microbiol Infect Dis 2006, 25:261-266.
18. Wang M., Wang J., Zhu Y., Xu Z., Yang K., Yang A., et al. Cellular immune response to Hantaan virus nucleocapsid protein in the acute phase of hemorrhagic fever with renal syndrome: correlation with disease severity. J Infect Dis 2009, 199:188-195.